Abbott snaps up replacement mitral valve maker Cephea

EKG rhythm
Cephea’s artificial valve is designed to be delivered through a vein in the leg, avoiding open-heart surgery. (Pixabay)

Abbott has exercised a three-year-old option to purchase Cephea Valve Technologies, a San Jose, California-based developer of minimally invasive mitral heart valve replacements.

The financial terms of the acquisition were not disclosed. Abbott previously gave Cephea an unrevealed amount of money for the option in mid-2015 to help build upon its MitraClip repair franchise, one of the company’s top performers.

"The acquisition of Cephea builds on Abbott's strong position in structural heart therapies and is consistent with our strategy to develop comprehensive treatments for people with mitral valve disease," said Michael Dale, vice president of Abbott's structural heart business.


Webinar: Meet the Challenge of Complex Protein Expression

As market demand continues to rise for more potent and effective therapeutics, biologic pipelines are evolving from standard antibody formats to next-generation biologics (NGBs). In this webinar we will discuss and demonstrate application through case studies, two significant enhancements to Lonza’s GS Xceed® expression system to help address the challenges of NGBs.

Cephea’s artificial valve is designed to be delivered through a vein in the leg, to replace a leaky or diseased mitral valve to restore normal blood blow through the heart.

Mitral valve disease is the most common heart valve problem, and affects more than 4 million people in the U.S., according to Abbott, which expects the market to become a multibillion-dollar segment in the coming years.

"Cephea's novel approach to replace the mitral valve adds to our other catheter-based technologies and is being developed to provide an additional option for patients who suffer from this difficult-to-treat disease," Dale said.

Abbott’s 2015 investment in Cephea was made alongside a $250 million acquisition deal for Tendyne, makers of a bioprosthetic mitral valve system.

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.